Whitefort Capital Management LP Acquires 373,949 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Whitefort Capital Management LP raised its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,241,916 shares of the biopharmaceutical company's stock after acquiring an additional 373,949 shares during the quarter. Arbutus Biopharma makes up 20.8% of Whitefort Capital Management LP's investment portfolio, making the stock its biggest holding. Whitefort Capital Management LP owned about 6.99% of Arbutus Biopharma worth $43,301,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. E Fund Management Co. Ltd. acquired a new stake in Arbutus Biopharma during the 4th quarter worth approximately $34,000. Xponance Inc. acquired a new stake in Arbutus Biopharma during the 4th quarter worth approximately $34,000. Raymond James Financial Inc. acquired a new stake in Arbutus Biopharma during the 4th quarter worth approximately $34,000. Cibc World Markets Corp acquired a new stake in Arbutus Biopharma during the 4th quarter worth approximately $45,000. Finally, Hsbc Holdings PLC acquired a new stake in Arbutus Biopharma during the 4th quarter worth approximately $55,000. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Stock Performance

NASDAQ ABUS remained flat at $3.22 during mid-day trading on Friday. The company had a trading volume of 532,457 shares, compared to its average volume of 996,433. Arbutus Biopharma Co. has a 12-month low of $2.71 and a 12-month high of $4.73. The firm has a market cap of $616.72 million, a P/E ratio of -7.49 and a beta of 1.50. The stock has a 50-day moving average price of $3.27 and a 200 day moving average price of $3.35.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.04). Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The firm had revenue of $1.76 million during the quarter, compared to analysts' expectations of $2.54 million. Sell-side analysts expect that Arbutus Biopharma Co. will post -0.39 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ABUS shares. Chardan Capital reissued a "buy" rating and set a $5.00 target price on shares of Arbutus Biopharma in a research note on Friday, March 28th. Wall Street Zen raised Arbutus Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, March 29th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Arbutus Biopharma currently has a consensus rating of "Moderate Buy" and an average target price of $5.50.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.